- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Emperor preserved trial: Empagliflozin effective to treat heart failure
Overview
The EMPEROR-Preserved trial reports empagliflozin is superior to placebo in improving heart failure outcomes among patients with symptomatic stable heart failure with preserved ejection fraction, irrespective of diabetes status.
Incidence of Heart Failure in India appears to rise and estimates of prevalence range from 1.3 million to 4.6 million, with an annual incidence of 0.49–1.8 million. Several drugs are being investigated to manage heart failure.
The safety and efficacy of empagliflozin in patients with symptomatic heart failure was assessed in 2997 Patients randomized in a 1:1 design to either empagliflozin 10 mg or matching placebo of 2,991 patients in the trial.
Health-related quality of life in patients treated with empagliflozin had significant improvement in patients with meaningful improvements was reported in American College of Cardiology journal. Most routinely used drugs for Heart failure with reduced ejection fraction have not shown to be effective among patients, however this drug marks the change of treatment options.
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)